Paroxetine
- Generic Name
- Paroxetine
- Brand Names
- Paxil, Pexeva
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20FNO3
- CAS Number
- 61869-08-7
- Unique Ingredient Identifier
- 41VRH5220H
- Background
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this...
- Indication
Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the tr...
- Associated Conditions
- Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
Luteal Phase Administration of Paroxetine for the Treatment of PMDD
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Registration Number
- NCT00620581
- Locations
- 🇨🇦
Women's Health Concerns Clinic, Hamilton, Ontario, Canada
Dementia Antipsychotics And Antidepressants Discontinuation Study
- Conditions
- Interventions
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Sykehuset Innlandet HF
- Target Recruit Count
- 149
- Registration Number
- NCT00594269
- Locations
- 🇳🇴
Sykehuset Innlandet HF, Reinsvoll, Oppland, Norway
🇳🇴Diakonihjemmets Hospital, Oslo, Norway
🇳🇴Ullevaal University Hospital, Oslo, Norway
Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- Durham VA Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT00560612
- Locations
- 🇺🇸
Durham VAMC, Durham, North Carolina, United States
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT00557622
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria
- Conditions
- Interventions
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2007-12-07
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 24
- Registration Number
- NCT00516113
- Locations
- 🇸🇪
The Psychiatric clinic, Sahlgrenska University Hospital, Göteborg, Sweden
Duloxetine Versus Paroxetine for Major Depression
- Conditions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2007-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 480
- Registration Number
- NCT00489775
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China
A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 501
- Registration Number
- NCT00463242
- Locations
- 🇵🇷
Novartis Investigative Site, Hato Rey, Puerto Rico
A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks
- Conditions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- Beth Israel Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT00457106
- Locations
- 🇺🇸
Beth Israel Medical Center, New York, New York, United States
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
- Conditions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00456898
AV650 Drug-Drug Interaction Study
- Conditions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2007-09-17
- Lead Sponsor
- Avigen
- Target Recruit Count
- 30
- Registration Number
- NCT00456560
- Locations
- 🇺🇸
Covance Global Clinical Pharmacology Inc., San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.